Tumor sample context
Tumor type, collection site, sample condition, expected timing and available ethics documentation.
Breast cancer PDO
Patient-derived breast tumor organoids for single-agent and combination studies, with PDO 2.0 / ALI considered when immune context is relevant.
ERPRKi67PD-L1
Model source
Patient breast tumor tissue, with sample quality and subtype incorporated into model planning
Culture / format
PDO 1.0 · PDO 2.0 / ALI study format
Supporting evidence
TRiCBIO culture, passaging and study data
Model characterization
How the model is established and characterized
Source-tissue and organoid imaging plus lineage/identity markers characterize the model; functional readouts are selected for the candidate mechanism and study objective.
View imageReceptor and proliferation phenotype: DAPI, ER and Ki67 show nuclear, receptor-associated and proliferative features in this breast PDO and provide a baseline for subtype-informed study design.
Model & assay data
View imageThree complementary viewsSource-tissue H&EPDO bright-field morphologyPDO histology
Source tissue and PDO: source-tissue H&E, PDO bright-field and PDO histology are viewed together to assess morphological correspondence in this model.
Model & assay dataStudy planning
From study objective to model and assay plan
Tumor type, sample condition, candidate and intended comparison guide the culture format, controls and assays.
Candidate and study objective
Modality, dosing plan, controls and the response or comparison the study should address.
Assays and deliverables
Planned histology, flow, molecular or functional assays, together with preferred data and report formats.
Study design
Compare breast cancer candidates in subtype and receptor context
Molecular subtype, sampling site and prior treatment directly shape breast PDO studies. Study design integrates source-tissue context, receptor phenotype, model identity and culture quality, and drug mechanism.
Review pathology and treatment context
Review ER, PR and HER2 context, primary or metastatic site, sampling method and prior treatment to define the decision.
Select PDO 1.0, PDO 2.0 or a combined design
Choose around candidate mechanism, required cellular context, spatial information and endpoints; the two systems can also be used sequentially or in parallel.
Design treatment around mechanism
Set dose, timing, positive/negative controls and combinations around small molecules, antibodies, ADCs or immunotherapies.
Combine phenotype and function
Compare candidates using receptor and proliferation markers, histology, viability, cytokines or flow in context.
Research applications
Recommended applications
- Single-agent and combination efficacy
- ICB-related studies with project-specific PDO 2.0 / ALI
- Molecular biomarkers and source-tissue/PDO morphology
Assays & QC
Tumor identity, efficacy and immune readouts
Key markers
ERPRKi67PD-L1
Available assays
- H&E / IHC / IF
- Viability
- Cytokines
- Flow cytometry
QC approach
QC combines tissue morphology, receptor/proliferation markers and project-relevant functional readouts.
Study & delivery
Model characterization, treatment data and reporting
Choose model establishment, expansion or a TRiCBIO-run efficacy study. Typical deliverables include raw data and an analysis report.
Related solutions
Related study options
PROJECT DISCUSSION
Discuss a breast cancer PDO study
Tumor type, sample status, candidate profile and comparison endpoints determine the culture format, controls, assay panel and deliverables for the breast cancer PDO.